Although information on efficacy and adverse drug reactions is lacking ,
ribavirin has been used empirically for the treatment of severe acute respiratory syndrome ( SARS ) . <S>
We report common adverse events in 110 patients with suspected or probable SARS
who were treated with ribavirin . <S>
Sixty - one percent of the patients had evidence of hemolytic anemia ,
and hypocalcemia and hypomagnesmia were reported in 58 % and 46 % of patients , respectively . <S> <P>
